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The therapeutic management of cluster headache is based on a very stable
triad of drugs. Acute treatment has, in subcutaneous sumatriptan, its gold
standard if compared to pure oxygen or indomethacin. Preventative treat-
ment is based on verapamil at high doses (‡ 360 mg) and is a gold standard
if compared to lithium carbonate or topiramate. Transitional treatments,
based on the short-term use of corticosteroids with either systemic or local
administration (GON), can be useful for the suppression of most resistant
cluster periods, but with a well-known carry-over phenomenon related to
the length of the cluster period itself. The role of invasive or noninvasive neu-
romodulation approaches must still be determined on a large scale; therefore,
its use is not recommended as of yet. Lifestyle changes, including alcohol
avoidance during the active phase of the disease, sleep hygiene and use of
vasodilation drugs, should be carefully considered and the patients should
be fully informed.
Keywords: cluster headache, corticosteroids, GON block, neurostimulation, oxygen,
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1. Cluster headache, very popular but still underdiagnosed
Cluster headache (CH) is the most common of the trigeminal autonomic cephalal-
gias (TACs) [1]. CH is a strictly lateralized and devastating periorbital headache,
characterized with a very severe, excruciating pain and the presence of ipsilateral
cranial autonomic symptoms, such as conjunctival injection, lacrimation and rhi-
norrhea. Lifetime prevalence is 1/1000 and a progressive reduction of the male/
female ratio over the past decades has been demonstrated and is now 2.1:1 [2].
The peculiar timing over the day (1 -- 8 attacks), in the entire active cluster period
lasting 60 -- 90 days, and in the span of the year particularly with the seasonal
changes, renders this headache unique, very easy to diagnose and differentiate
from other TACs [1]. Nevertheless, only 1/3 of these patients received the diagnosis
of CH, with a diagnostic delay of 5.3 years and more than 2/3 of them never
received any treatment. The most frequent clinical errors behind this delay are
trigeminal neuralgia, migraine without aura, headache attributed to idiopathic
intracranial hypertension, tension-type headache, depression, dental and sinus
pathologies [3]. The strict laterality of pain, even though considered a clinical
marker, might shift sides in a minority of patients, either within the bouts of the
same cluster period or between the bouts of different cluster periods [4].
The natural history of this illness, which generally begins between 20/30 years of
age, shows seasonal cluster periods with an unpredictable variability of their circa-
annual rhythms. This leads to overestimate the effect of the administered therapy
showing often a spontaneous prolonged remission. Only 10% of patients with
episodic cluster headache (ECH) develop a chronic form (CCH) (> 180 days/
year) and even fewer develop refractory or medically resistant chronic cluster head-
ache (rCCH) [5].
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The strong evidence supporting the pathophysiology of CH
revolves around the suggestion of a posterior hypothalamic dys-
function (anatomic, endocrine, genetic, neuro-immunological
and functional imaging). Scientists are therefore oriented
toward its involvement [6] even if this solid hypothesis has
been recently re-interpreted as an epiphenomenon [7].
Rare cases of secondary cluster-like headaches are ascribable
to pituitary tumors, fungal cysts or dissection of the internal
carotid artery and are extremely challenging for the clinician,
also the expert one [8].
2. Early therapeutic management needed, but
delayed diagnosis frustates it
CH therapeutic management varies according to the three
forms previously cited (ECH, CCH, rCCH).
Acute, transitional and preventative treatments can be
applied to both ECH and CCH. The gold standard for the
acute treatment of CH is subcutaneous sumatriptan, able to
dissolve the attack in a handful of minutes [9-11]. Patients
with previous ischemic and cardio-cerebral pathologies must
be excluded from such therapy. Other sumatriptan or zolmi-
triptan formulations do not show, from a clinical point of
view, the needed rapidity and completeness of action despite
reported scientific evidence [12-16].
Indomethacin may, in some cases, be a helpful alternative
even if there is no clear-cut evidence of its efficacy for CH.
This drug is generally not recommended by international
guidelines, and should not be used in the presence of arterial
hypertension or gastric bleeding [17].
Pure oxygen inhalation at a flow of 7 -- 15 l/min, delivered
by facemask, possibly with reservoir for no more than 20 min,
is safer and, on its own, showed a very meaningful effect on
CH attack. The main concern is that, in some patients, it
may delay the attacks rather than abort them. Unfortunately,
oxygen presents applicative limitations in terms of
portability [18,19].
Hyperbaric oxygen has been reported as a rescue alternative
in chronic CH where other options resulted inopportune, but
its intrinsic limits sum up with the lack of accessibility [20].
Recently, vagal nerve stimulation (VNS) has been proposed
for the treatment of the attack and for prophylaxis, both in
episodic and chronic CH. The initial experience indicates
that noninvasive vagus nerve stimulation may be practical
and effective as an acute and preventive treatment in CCH.
This Class IV evidence technique should be confirmed by
randomized controlled trials (RCTs) [21].
3. Transitional therapy is necessary, but
beware of the carry-over phenomenon
In clinical situations showing a cluster period lasting up to
4 -- 5 months with a risk of chronicization, transitional block
of the greater occipital nerve with long-acting corticosteroids
can be considered. This option may lead to a clinical
amelioration and should be repeated cyclically. The limitation
of this approach resides in the nonfamiliarity or the reluctance
of the headache expert toward this mini-invasive but very easy
technique [22].
Cortisone per os (prednisone 1 mg/kg with a tapering regi-
men) is still widely used but inadvisable since it causes the
carry-over phenomenon of the cluster or, even worse, a violent
rebound.
4. Preventative treatment as a cornerstone
The gold standard of preventative treatment is still verapamil
taken at medium-high doses (from 360 mg/day up to
960 mg). The starting dose is always 360 mg ex abrupto for
patients with a clear absence of bradycardia (< 50 bpm), hypo-
tension (< 100/60 mmHg) or other cardiac arrhythmias
(atrioventricular block). Uncomfortable adverse effects of
ankle edema [23] are tolerated by patients considering
verapamil’s fast action, less than 72 h to crush the bouts.
Lithium is less handy than verapamil. It needs a longer
latency period (up to 10 -- 15 days) because of the need for pro-
gressive titration up to 900 -- 1200 mg/day and a burdensome
bimonthly evaluation of lithium levels (0.8 -- 1.2 µmol/l);
referential parameter for an effective therapeutic action,
but with important inter-individual variations. Serious side
effects are hypothyroidism, diabetes insipidus and mental
confusion.
The use of topiramate at optimal dosage (within 100 and
200 mg/day) is strongly limited by its serious side effects
(slow tritation, serious cognitive impairment) and contraindi-
cations (glaucoma, kidney stones, severe temporary weight
loss and irreversible drop of visual acuity).
Melatonin may be included as preventative treatment on
the basis of a small pilot RCT that demonstrated its clinical
relevance in CH [24].
Other supposed preventative therapies with gabapentin,
baclofen, levetiracetam, pizotifen, sodium valproate, testoster-
one, misoprostol, civamide, warfarin, candesartan, acupunture
or other drugs no longer available, like dihydroergotamine and
methysergide, are not clinically relevant.
The mentioned preventative treatments must be started at
the first sight of activation/re-activation of the cluster period
and must be continued for a period equal to 1.5 of the histor-
ical length of the patient’s single cluster. Shorter treatments
might produce a temporal shift of the active period, even if
this re-firing has a lower intensity. Therefore, the most appro-
priate semantic definition of the preventative therapy should
be “control/suppression therapy” of the cluster period.
5. Beyond the reliable pharmacological triad
A hypothetical tripod for the therapy of CH can be summa-
rized in sumatriptan, verapamil and corticosteroids. New
therapeutic opportunities are now enriching the literature on
the subject of migraines. These new compounds, monoclonal
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antibodies against calcitonin gene-related peptide, could soon
be available as preventative treatment of migraine [25] and,
hopefully, for CH as well.
Furthermore, another important topic to be considered is
patients’ knowledge regarding possible triggers. Patients
should be educated to avoid any substance that, in the active
phase of CH, might work as a strong activator of the bouts,
like alcohol, nitroderivative drugs used for the treatment of
angina pectoris, and phosphodiesterase inhibitors used for
erectile dysfunction.
Therefore, only with better education of physicians at the
different care levels (general practitioners, neurologists) and
of patients, an early diagnosis is possible, since an adequate
treatment of CH cuts the risk of chronicization to a mini-
mum. A practical concise scheme for the management of
CH is summarized in Figure 1.
It goes without saying that the introduction of new, more
manageable and efficacious preventative drugs might stop
the therapeutic alarm that often hovers around this impressive
and psychologically destabilizing painful pathology. These
drugs may also reduce the chronicization rate often linked
to an inefficacy ab initio of the therapeutic preventative
opportunities now available.
Another point to be mentioned regards the new invasive
and noninvasive neuromodulation approaches for CCH.
Despite promising new data, the European Headache
Federation recommends caution in using these techniques [26]
because only few controlled studies have, as yet, been carried
out. It is important to avoid the disillusion produced in
CCH patients when, more than 10 years ago, the scientific
community celebrated as decisive, an extremely invasive and
harmful therapeutic proposal [27], now abandoned [26,28].
Lastly, going beyond the actual management of CH, VNS
seems to be promising but is still classified at Class IV evi-
dence [21], while sphenopalatine ganglion stimulation shows
contrasting evidence [29,30] that needs to be confirmed and
validated through RCTs.
On the other hand, new hopes rely on the future applica-
tion of an RCT efficacy study of LY2951742 in episodic
CH. This drug, if approved, could change the management
of CH rendering it very easy to use through a subcutaneous
administration every 30 days [31].
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Management road for cluster headache
Preventative treatment
Verapamil (+++), lithium
carbonate (++), Topiramate (+)
Neuromodulation treatment
VNS, SPG, ONS, SCS
Transitional treatment
Corticosteroids (oral, GON, iv, im)
Acute treatment
Sumatriptan 6 mg sc, pure oxygen,
indomethacin
Lifestyle changes
Avoidance of alcohol, sleep changes
and vasodilation drugs
Figure 1. Comprehensive management of cluster headache.
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